1 Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Cologne, Germany.
2 HNO-Zentrum Neuss, Neuss, Germany.
Otolaryngol Head Neck Surg. 2018 Feb;158(2):295-302. doi: 10.1177/0194599817728476. Epub 2017 Sep 5.
Objective Assessment of the value of transoral laser microsurgery (TLM) compared with open surgery (OS) for early stage squamous cell carcinoma of the glottic larynx with special regard to involvement of the anterior commissure (AC). Study Design Case series with chart review. Setting Tertiary care otolaryngology clinic. Subjects and Methods Review of clinicopathological data of all patients with previously untreated T1a, T1b, and T2 glottic squamous cell carcinoma of the larynx who were consecutively enrolled over a 10-year period (January 1, 1992, to December 31, 2002). Results Local recurrence rate was 20.4% (10 of 49) for TLM and 10.7% (3 of 28) for OS. Comparison of the TLM and OS groups regarding local recurrence rates revealed a significant difference only for tumors invading the AC ( P = .046). Within the TLM group, tumors with involvement of the AC showed a significantly higher recurrence rate (38.1%; 8 of 21) compared with tumors without involvement of the AC (7.1%; 2 of 28; P = .008). In the OS group, involvement of the AC revealed no significant difference ( P = .45). The overall survival in both groups was comparable in both groups (TLM, 93.9%; OS, 89.3%; P = .47). Conclusion TLM and OS are equally effective surgical treatments for early stage glottic cancer without involvement of the AC, with selection of treatment based on pretreatment endoscopy. However, TLM is associated with less morbidity. In case of invasion of the AC, OS yields lower recurrence rates.
评估经口激光显微手术(TLM)与开放性手术(OS)治疗早期声门型喉鳞状细胞癌(尤其是累及前联合的肿瘤)的价值。
病例系列回顾。
三级耳鼻喉科诊所。
回顾了 10 年间(1992 年 1 月 1 日至 2002 年 12 月 31 日)所有未经治疗的 T1a、T1b 和 T2 声门型喉鳞状细胞癌患者的临床病理资料。
TLM 组局部复发率为 20.4%(49 例中的 10 例),OS 组为 10.7%(28 例中的 3 例)。比较 TLM 和 OS 组的局部复发率,仅在累及前联合的肿瘤中差异有统计学意义(P =.046)。在 TLM 组中,累及前联合的肿瘤复发率明显高于未累及前联合的肿瘤(38.1%,21 例中的 8 例)(P =.008)。在 OS 组中,累及前联合与无累及前联合的肿瘤复发率差异无统计学意义(P =.45)。两组的总生存率无显著差异(TLM 组 93.9%,OS 组 89.3%;P =.47)。
对于未累及前联合的早期声门型喉癌,TLM 和 OS 是同样有效的外科治疗方法,可根据术前内镜检查选择治疗方法。然而,TLM 与较低的发病率相关。在前联合受累的情况下,OS 可降低复发率。